Swipe on the arrows on the pictures in the image carousel below to see pictures and watch videos from the event.
Main target groups: Researchers and students at UiO, OUS and Ahus.
In 2017 UiO:Life Science appointed the first convergence environments – interdisciplinary research groups that will solve grand challenges. Three of the groups are based on close collaboration between UiO and Oslo University Hospital (OUS). At this seminar you will hear short talks from different disciplines within the convergence environments. Also, each environment has invited an international speaker in the front of their research fields.
Programme
Registration fron 12.30
13.00 Session 1 |
|
Professor Finn-Eirik Johansen, chairperson the board UiO:Life Science and vice dean research the Faculty of Mathematics and Natural Sciences, UiO Chair |
Personalised cancer therapies
Professor Trevor Graham, Barts Cancer Institute UK Predicting cancer evolution Graham?s lab measures the patterns of clonal evolution that define carcinogenesis and develops novel mathematical tools for analysis and prediction. By characterising tumour evolution, his lab aims to find better ways to determine prognosis and more effective ways to treat cancers. |
Three short presentations form the convergence environment
|
14.05 Short coffee break |
14.25 Session 2 |
Organ on a chip and nano-devices
Dr. Peter Loskill: Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Germany Stem cell based microphysiological Organ-on-a-Chip systems as in vitro models of human tissue Loskill works at the borders where physics and engineering meet biology and medicine. Using human induced pluripotent stem cells (iPS cells) the aim is to develop in vitro disease-specific model tissues and organs to be used for high content drug screening and patient specific medicine. Currently his lab id interested in “heart-on-chip” and “fat-on-chip” platforms. |
Three short presentations form the convergence environment
|
Epigenetics and bioethics of human embryonic development
Professor Mary Herbert, Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, UK Preventing germline transmission of mitochondrial DNA mutations – therapeutic potential and ethical considerations Herbert leads a team of clinical and research scientists working side by side in a programme of basic, translational and clinical science. The aim is to improve the treatment and understanding of infertility and extending the scope of reproductive technologies to prevent transmission of disease. She has developed a groundbreaking technique to transfer healthy mitochondria to fertilized embryos. |
Three short presentations from the convergence environment
|
16.15–17.00 Refreshments and mingling |
